• 1. Emerging investigator series: first-principles and thermodynamics comparison of compositionally-tuned delafossites: cation release from the (001) surface of complex metal oxides?
  Joseph W. Bennett,Diamond T. Jones,Blake G. Hudson,Joshua Melendez-Rivera,Robert J. Hamers,Sara E. Mason Environ. Sci.: Nano, 2020,7, 1642-1651
• 2. Emulsion soft templating of carbide-derived carbon nanospheres with controllable porosity for capacitive electrochemical energy storage?
  M. Zeiger,N. J?ckel,P. Strubel,L. Borchardt,R. Reinhold,W. Nickel,J. Eckert,V. Presser,S. Kaskel J. Mater. Chem. A, 2015,3, 17983-17990
• 3. Establishment and implications of a characterization method for magnetic nanoparticle using cell tracking velocimetry and magnetic susceptibility modified solutions
  Huading Zhang,Lee R. Moore,Maciej Zborowski,P. Stephen Williams,Shlomo Margel,Jeffrey J. Chalmers Analyst, 2005,130, 514-527
• 4. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 5. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608

Obeticholic Acid Metabolite UPF-1443 (CAS No. 863239-61-6): An Emerging Therapeutic Agent in the Treatment of Liver Diseases

Obeticholic acid metabolite UPF-1443 (CAS No. 863239-61-6) is a significant compound in the field of hepatology, particularly in the treatment of liver diseases such as primary biliary cholangitis (PBC) and non-alcoholic steatohepatitis (NASH). This metabolite, derived from obeticholic acid (OCA), has garnered considerable attention due to its potential therapeutic benefits and unique pharmacological properties.

Obeticholic acid (OCA) is a potent agonist of the farnesoid X receptor (FXR), a nuclear receptor that plays a crucial role in regulating bile acid, lipid, and glucose metabolism. The activation of FXR by OCA has been shown to reduce bile acid synthesis, improve liver function, and ameliorate inflammation and fibrosis. However, the metabolism of OCA into its active metabolites, such as UPF-1443, further enhances its therapeutic potential by modulating additional pathways and extending its biological effects.

UPF-1443 has been extensively studied for its role in the treatment of PBC, a chronic liver disease characterized by the progressive destruction of small bile ducts. Clinical trials have demonstrated that UPF-1443 can significantly improve biochemical markers of liver function, such as alkaline phosphatase (ALP) and gamma-glutamyl transferase (GGT), which are often elevated in PBC patients. Moreover, UPF-1443 has shown promise in reducing pruritus, a common and distressing symptom associated with PBC.

In addition to its efficacy in PBC, UPF-1443 has also been evaluated for its potential in treating NASH, a condition characterized by liver inflammation and fat accumulation without excessive alcohol consumption. Preclinical studies have indicated that UPF-1443 can reduce hepatic steatosis, inflammation, and fibrosis by modulating FXR-dependent pathways. These findings suggest that UPF-1443 may offer a novel therapeutic approach for NASH patients who currently lack effective treatment options.

The pharmacokinetic properties of UPF-1443 have been extensively characterized. It is rapidly absorbed following oral administration and undergoes extensive first-pass metabolism. The metabolite is primarily excreted via bile and feces, with minimal renal excretion. This metabolic profile contributes to its favorable safety profile and reduced risk of systemic side effects.

Clinical trials evaluating the safety and efficacy of UPF-1443 have reported promising results. In phase II trials for PBC, patients treated with UPF-1443 showed significant improvements in liver function tests and a reduction in pruritus severity compared to placebo. Similarly, phase II trials for NASH have demonstrated that UPF-1443 can improve liver histology and reduce markers of liver injury.

The mechanism of action of UPF-1443 involves multiple pathways beyond FXR activation. Recent studies have shown that it can also modulate the expression of genes involved in lipid metabolism, inflammation, and fibrosis. For instance, UPF-1443 has been found to downregulate pro-inflammatory cytokines such as tumor necrosis factor-alpha (TNF-α) and interleukin-6 (IL-6), which are key mediators of liver inflammation. Additionally, it can inhibit the activation of hepatic stellate cells, which are responsible for collagen production and fibrosis progression.

The development of UPF-1443 as a therapeutic agent has also focused on optimizing its formulation to enhance bioavailability and reduce side effects. Various formulations, including extended-release tablets and oral suspensions, are being evaluated to improve patient compliance and treatment outcomes. These efforts aim to ensure that patients receive the maximum benefit from this promising compound while minimizing potential adverse effects.

In conclusion, Obeticholic acid metabolite UPF-1443 (CAS No. 863239-61-6) represents a significant advancement in the treatment of liver diseases such as PBC and NASH. Its unique pharmacological properties, combined with its favorable safety profile and multiple mechanisms of action, make it a promising candidate for further clinical development. As research continues to uncover new insights into the biology of liver diseases, the role of compounds like UPF-1443^{(1), (2), (3))(2), (3))}

• 82473-24-3(3-(3-Cholamidopropyl)dimethylammonio-2-hydroxy-1-propanesulfonate)
• 496-65-1((R)-Pantetheine)
• 15324-65-9(Ethanesulfonic acid,2-[[(3a,5b)-24-oxo-3-(sulfooxy)cholan-24-yl]amino]-)
• 125378-99-6(Ethanesulfonic acid,2-[[(3a,5b,7a,12a)-7-[(4-azidobenzoyl)amino]-3,12-dihydroxy-24-oxocholan-24-yl]amino]-(9CI))
• 103683-18-7(1-Dodecanaminium,N-[2-[acetyl(3-sulfopropyl)amino]ethyl]-N,N-dimethyl-, inner salt)
• 75621-03-3(Chaps)
• 14605-22-2(Tauroursodeoxycholate)
• 142608-64-8(Ethanesulfonic acid,2-[[(1b,3a,5b,7a)-1,3,7,14-tetrahydroxy-24-oxocholan-24-yl]amino]-(9CI))
• 516-35-8(Taurochenodeoxycholic acid)
• 103-47-9(CHES)